Daily aspirin associated with a reduced risk of hepatocellular carcinoma in patients with non-alcoholic fatty liver disease: a population-based cohort study
Journal
EClinicalMedicine
Journal Volume
61
Pages
102065
Date Issued
2023-07
Author(s)
Abstract
Emerging laboratory and animal studies suggest that aspirin may prevent non-alcoholic fatty liver disease (NAFLD)-related hepatocellular carcinoma (HCC), however clinical evidence remains lacking.
Subjects
Antiplatelet; Chemoprevention; Liver cancer; Prevention
Type
journal article